InvestorsHub Logo

ilovetech

10/12/22 5:29 PM

#521459 RE: hyperopia #521456

I'm glad. I'll leave it there.

biosectinvestor

10/12/22 5:36 PM

#521461 RE: hyperopia #521456

Sometimes many of those things are actually all there, but the narrative is missing and a lot of retail want narrative. There are also circumstances where narrative can’t exactly be given. Or where narrative in the past has not been helpful because many factors are simply still open to a lot of discretion with new technologies and managers. Managers who come from large companies are used to huge budgets and a much easier prices that creates predictability. But the largest companies are also not innovating at the cutting edge, they buy it later, once they determine that the main risks are mostly gone. Then all of that is very much easier with large budgets, redundant personnel to expedite work, and plenty of money for necessary additional expertise when it is needed. Often they will have direct and easy access to former top officials at a relevant agency, people who know who will be doing what and how they work.

Truthfan

10/12/22 5:44 PM

#521465 RE: hyperopia #521456

Apologies if this is duplicate:

Re: Charles River at Cell & Gene Meeting on the Mesa

nAAVigation platform will be launched at the Cell & Gene Meeting on the Mesa

https://www.businesswire.com/news/home/20221010005058/en/Charles-River-Launches-nAAVigation-Vector-Platform-to-Accelerate-Gene-Therapy-Programs

Doc logic

10/12/22 11:14 PM

#521579 RE: hyperopia #521456

hyperopia,

Looks like Advent, INMune Bio and NWBO are missing but Charles River Labs is holding down the fort with the worldwide footprint. I wonder how many of those other names will be missing in the next 4 years. Best wishes.